Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imipenem + cilastatin + relebactam
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Imipenem + cilastatin + relebactam** is an intravenous fixed-dose antibacterial combination marketed as **Recarbrio**. Imipenem is a carbapenem that inhibits bacterial cell-wall synthesis through penicillin-binding-protein inhibition; cilastatin inhibits renal dehydropeptidase 1, preventing renal metabolism of imipenem; and relebactam is a diazabicyclooctane beta-lactamase inhibitor that protects imipenem from susceptible class A and class C serine beta-lactamases, including Klebsiella pneumoniae carbapenemase. Developed and marketed by Merck, it is approved for susceptible Gram-negative infections including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated urinary tract infection including pyelonephritis, and complicated intra-abdominal infection in defined patient populations. ([merck.com](https://www.merck.com/product/usa/pi_circulars/r/recarbrio/recarbrio_pi.pdf))
- Brand names
- Recarbrio
- Other names
- IMI/RELimipenem + cilastatin + relebactamimipenem-cilastatin-relebactamimipenem/cilastatin/relebactamimipenem/relebactamrelebactam/imipenem/cilastatin
02
Targets
PBP (Penicillin-binding protein family)DPEP1 (Dehydropeptidase 1)AmpC (AmpC beta-lactamase)
Beyond the preview
Go deeper on imipenem + cilastatin + relebactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imipenem + cilastatin + relebactam.